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Abstract
Background: Breast cancer in the U.S. - estimated at 232,670 incident cases in 2014 - has the highest aggregate
economic burden of care relative to other female cancers. Yet, the amount of cost attributed to diagnostic/
preoperative work up has not been characterized. We examined the costs of imaging and biopsy among women
enrolled in Medicare who did and did not receive diagnostic/preoperative Magnetic Resonance Imaging (MRI).
Methods: Using Surveillance, Epidemiology and End Results (SEER)- Medicare data, we compared the per capita
costs (PCC) based on amount paid, between diagnosis date and primary surgical treatment for a breast cancer
diagnosis (2005–2009) with and without diagnostic/preoperative MRI. We compared the groups with and without
MRI using multivariable models, adjusting for woman and tumor characteristics.
Results: Of the 53,653 women in the cohort, within the diagnostic/preoperative window, 20 % (N = 10,776)
received diagnostic/preoperative MRI. Total unadjusted median costs were almost double for women with MRI vs.
without ($2,251 vs. $1,152). Adjusted costs were higher among women receiving MRI, with significant differences
in total costs ($1,065), imaging costs ($928), and biopsies costs ($138).
Conclusion: Costs of diagnostic/preoperative workups among women with MRI are higher than those without.
Using these cost estimates in comparative effectiveness models should be considered when assessing the benefits
and harms of diagnostic/preoperative MRI.
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Background
The high incidence of female breast cancer in the United
States (U.S.) – estimated to affect 232,670 women in
2014 - [1] results in an aggregate economic burden of
care relative to other cancers that is among the highest
of all cancers in women [2]. While the majority of breast
cancer treatment related costs occur in the first
12 months following diagnosis [2], costs for women as
they are diagnosed and deciding upon initial diagnostic/
preoperative treatment have not been characterized.
Women with breast cancer and their providers face a
number of decisions during the diagnostic and preopera-
tive period, including which diagnostic testing, workup
and primary treatment options they will pursue. Cost is
one of several key factors cited by women with breast
cancer as important in weighing their breast cancer care
options [3].
Breast MRI has been reimbursed by Medicare and
other payers since 1991for women with a breast cancer
diagnosis, but only in the past 10 years has its use
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Fibecome widespread in clinical workup, increasing dra-
matically from an estimated 1 % in 2001 to between 21
and 50 % of breast cancer cases by 2010, with consider-
able regional variability [4–8]. The utility of breast MRI
is its high sensitivity – especially compared to mammog-
raphy – conferring an increased ability to determine ex-
tent of disease and detect occult cancer among women
with a breast cancer diagnosis [9]. However, breast MRI
also increases detection of benign and low malignant po-
tential lesions, which often require further workup in
order to make a final assessment [9]. This workup po-
tentially leads to increased costs that may not be offset
by other benefits. Preoperative MRI remains controver-
sial in part due to: lack of evidence for improved out-
comes, increased potential for false-positives, and the
possibility of surgical overtreatment [10–13]. Given the
increasing prevalence of breast MRI during the diagnos-
tic/preoperative period even amidst uncertainty regard-
ing harm and benefit tradeoffs, comparing effectiveness
against mammography (+/− ultrasound) is an identified
national priority [14].
Comparative effectiveness requires quantifying trade-
offs, a key dimension of which is cost, to determine the
relative benefits and harms of alternative clinical prac-
tices for use by individuals and public policy makers
[15]. In an era of increasingly constrained health care
budgets, developing a clear understanding of costs
weighed against clinical benefits is critical to rational re-
source use [15]. Fortunately, evidence of the clinical im-
pacts of preoperative breast MRI is accumulating
rapidly. Specifically, results from randomized controlled
trials and observational studies are providing insights
into preoperative MRI effects on cancer detection, bi-
opsy rates, biopsy yield, surgical treatment, and recur-
rence [4–6, 8, 16–21]. To date, there have been no
reports of the impact of diagnostic/preoperative breast
MRI on aggregate economic considerations particularly
compared to standard workup involving mammography
with or without ultrasound. Although the cost of a
breast MRI is about 10-times higher than a diagnostic
mammogram [22], the overall costs of workups includ-
ing breast MRI are not known and are relevant both for
women and for payers.
The objective of this study was to examine per capita
costs (PCC) of imaging and biopsy in the diagnostic/pre-
operative window among women enrolled in Medicare
who did and did not receive MRI during their breast
cancer diagnosis and preoperative workups. To address
this objective, we used a woman-centered framework
rather than societal, by measuring costs as the amount
actually paid for services, rather than a nationally-
standardized cost estimate. Thus, our aim was to esti-
mate costs at the woman level to provide estimates
when considering tradeoffs in the use of breast MRI.
The overall goal is to inform the current practice and
policy debates over use of diagnostic/preoperative MRI
from an economic standpoint to help guide clinically
appropriate use of this rapidly diffusing technology [4].
Methods
Data source
Surveillance, Epidemiology and End Results (SEER)-
Medicare data were used for this study (2004–2010).
The SEER program includes 17 population-based cancer
registries representing about 24 % of the U.S. population
that linked to Medicare administrative and health care
claims data [22]. The SEER-Medicare data have been used
to study health disparities, quality of care and cost of care
across the cancer control continuum [23]. All patient data
from the SEER-Medicare database used in this study were
de-identified. The analysis plan, manuscript and tables
were reviewed and approved by SEER- Medicare.
Ethics, consent and permissions
The study was approved by the Committee for Protection
of Human Subjects at Dartmouth College.
Study population
The study cohort included women aged 66 yrs. or older
at the time of an incident breast cancer diagnosis in
2005–2009 who were enrolled in Medicare with equal
parts A and B enrollment and not enrolled in an HMO
for one year before and six months after breast cancer
diagnosis (N = 71,193). Women were excluded if: they
lacked a pathologic breast cancer diagnosis confirmation,
the diagnosis source was a nursing home, they did not
receive cancer directed surgery, or no diagnostic biopsy
could be found (N = 7,248). Lastly, we required the
woman’s primary surgical treatment with either mastec-
tomy or breast conserving surgery (BCS) to occur within
six months of the diagnosis date (N = 7,496), resulting in
a final cohort of 56,449 women.
Definitions
The Medicare claim files (Outpatient and Carrier) were
used to obtain the biopsy at time of diagnosis, the pri-
mary surgical treatment, and comorbidities using Current
Procedural Terminology (CPT)/Healthcare Common
Procedure Coding System (HCPCS) and International
Classification of Diseases (ICD-9) diagnosis and pro-
cedure codes (Additional file 1: Appendix I). Comor-
bidities were defined by applying the Klabunde adaptation
of the Charlson Index [24]. Since the SEER cancer diagno-
sis date is defined only up to month and year, we deter-
mined the breast cancer diagnosis date (month, day and
year) from Medicare claims defined as the biopsy claim
date closest to the SEER diagnosis date. The time between
the initial breast imaging or biopsy within 60 days prior to
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diagnosis and the primary surgical treatment was defined
as the diagnostic/preoperative window. Within the diag-
nostic/preoperative window, we also distinguished two
periods: 1) the diagnostic period, defined as 60 days prior
to, and including, the diagnosis date; 2) the preoperative
period, defined as: post diagnosis date to initial surgery
date. The Outpatient and Carrier claim files were used to
capture breast imaging (MRI, Ultrasound, and Mammog-
raphy) and biopsies during the diagnostic/preoperative
window. We identified women as receiving diagnostic/
preoperative MRI if receipt of MRI occurred anytime dur-
ing the diagnostic/preoperative window. We included
MRI(s) prior to diagnosis since breast MRI performed
during the diagnostic period could potentially be used in
preoperative evaluation.
Costs (Outcome)
Costs associated with breast cancer care services deliv-
ered during the diagnostic/preoperative window were
obtained from the Medicare Carrier and Outpatient files
and were defined by payment amounts. We included all
costs associated with breast cancer care service claims
(e.g. all line items per claim for breast imaging and/or
biopsy). To calculate costs for each woman, we took the
sum of the line allowed amount variable from the
Carrier file (lalowamt) and the revenue center payment
amount and revenue center patient responsibility pay-
ment amount from the Outpatient file (pay and
ptntresp) over the diagnostic/preoperative window.
These variables combine to represent the total paid for
services of interest. We focus on total payments and do
not differentiate between payments from Medicare and
payments from other sources such as the patient, Medi-
gap policies or Medicaid.
Patient and cancer tumor characteristics
For patient and tumor characteristics of interest, we used
the SEER PEDSF (Patient Entitlement and Diagnosis
Summary File) to identify age at diagnosis, race, urban/
rural residence, SEER registry, year of diagnosis, and quar-
tiles of median household income for census tract, stage,
histology, grade, nodal status, estrogen receptor (ER) sta-
tus, and size. Age at diagnosis was categorized as follows
(in years): 66–69, 70–74, 75–79, 80–84, and 85+. Race
was categorized based on self-report within the Medicare
enrollment database and was categorized as “White”,
“Black”, or “Other”, using the categorical value provided
within the PEDSF. The category “Other” was collapsed
due to small numbers within the other race categories of:
Asian, Hispanic, North American Native, and Unknown.
Urban versus rural residence was provided in the PEDSF
based on patient residence at the time of diagnosis. Quar-
tiles of median household income for census tract of resi-
dence at the time of diagnosis were derived empirically
from the study population. All of the cancer/tumor char-
acteristics were taken from the PEDSF, based on SEER
registry data, and included: stage at diagnosis (0-IV),
histology (ductal, lobular, mixed, and other), grade (high,
intermediate, low), nodal status, (positive, negative), ER
status (positive, negative), an size in cm (<1, 1 to <2, 2 to
<5, and 5+). We dichotomized time from diagnoses to pri-
mary surgical treatment at the sample median.
Statistical analysis
We report median and interquartile range (IQR) of PCC
among women who received breast cancer care services
during the diagnostic/preoperative window by patient
and tumor characteristics. We mapped the median
amount ($) costs exceeded or fell below the overall me-
dian value for each SEER registry. Imaging alone and
biopsy alone services were mapped separately. Mapping
was performed using ArcGIS v10.1 with source geog-
raphy downloaded from the NCI GIS portal [25].
We used a multivariable regression model to compare
total PCC between the diagnostic/preoperative MRI
groups, adjusting for age, race, residential location, cen-
sus tract median income, SEER registry, comorbidities,
year of diagnosis, stage at diagnosis, grade, nodal status,
estrogen receptor status, tumor size, and time from diag-
nosis to primary surgical treatment. We estimated differ-
ences in adjusted mean costs using generalized linear
models (GLMs) with gamma distributed errors, identity
link function, and robust variance estimators to account
for the anticipated violation of the assumption of the
gamma mean-variance relationship common in cost
data. The model was repeated separately for the diagnos-
tic period and preoperative period described above.
Adjusted costs for each MRI group in the diagnostic and
preoperative periods were estimated from the fitted
GLMs by using predictive margins to standardize esti-
mated mean costs in each group to the overall distribu-
tion of patient and tumor characteristics observed in the
study sample included in each model [26]. Analyses were
conducted in SAS (SAS 9.3 System Options: Reference,
Second Edition. Cary, NC: SAS Institute Inc.; 2011) and
Stata/SE 12.1 (StataCorp. 2011. Stata 12 Base Reference
Manual. College Station, TX: Stata Press).
Results
Among the 56,449 women in the study cohort, a breast
imaging claim (mammogram, ultrasound or an MRI) for
53,653 women was found within the diagnostic/pre-
operative window. Of the 53,653, 20 % (N = 10,776) re-
ceived an MRI. Among the women defined in the MRI
group (N = 10,776), 1,713 women had an MRI in the
diagnostic period (16 %) and 9,196 women had an MRI
in the preoperative period (84 %). 133 women had an
MRI in both periods (12 %).
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The total unadjusted median diagnostic/preoperative
costs were almost double for women with a diagnostic/
preoperative MRI vs. without ($2,251 v. $1,152; Table 1).
Higher total median costs were found for each increase
in median income quartile, for urban versus rural, for
each successive year of diagnosis, for lower staged tu-
mors, smaller tumors, tumors with a positive nodal
status, and for women whose initial therapy was breast
conserving surgery (BCS) with radiation compared to
those with mastectomy or BCS alone (Tables 1 and 2).
Older age, increasing comorbidities, and having primary
surgical treatment closer to diagnosis were associated
with lower median costs (Tables 1 and 2). Similar trends
were found among the diagnostic/preoperative breast
MRI groups.
Among workups not including MRI, negligible devia-
tions from the median imaging costs were observed by
SEER registry. However, in the MRI group, wider posi-
tive imaging cost deviations were found in the SEER
registries of San Francisco, Los Angeles, and New Jersey.
Variation in the total median costs for SEER registries
are presented geographically as four distinct maps
Table 1 Among the female SEER-Medicare breast cancer cohorta (2005–2009; N = 56,449), median and interquartile range (IQR) per
capita costs for women within the diagnostic/preoperative window (N = 53,653) by patient characteristics, with and without breast
MRI
Total Median Costs MRI No MRI
(N = 53,653) (N = 10,776) (N = 42,877)
Characteristicsb of women N % Median IQR ($) Median IQR ($) Median IQR ($)
Total 53,653 100 % $1,353 (818–2,042) $2,251 (1,783–2,971) $1,152 (708–1,727)
Age at diagnosis (yrs.)
66–69 11,130 21 % $1,553 (969–2,268) $2,307 (1,810–3,097) $1,241 (778–1,821)
70–74 13,949 26 % $1,447 (892–2,146) $2,271 (1,806–3,045) $1,211 (760–1,781)
75–79 12,713 24 % $1,362 (837–2,036) $2,223 (1,759–2,934) $1,178 (733–1,767)
80–84 9,633 18 % $1,220 (734–1,871) $2,201 (1,733–2,742) $1,082 (668–1,654)
85+ 6,228 12 % $1,024 (608–1,625) $2,057 (1,660–2,687) $948 (576–1,459)
Race
White 47,150 89 % $1,360 (827–2,046) $2,243 (1,785–2,955) $1,154 (711–1,722)
Black 3,732 7 % $1,293 (757–1,946) $2,272 (1,674–3,288) $1,162 (697–1,779)
Otherc 2,741 5 % $1,317 (761–2,065) $2,331 (1,799–3,025) $1,099 (677–1,711)
Residential location
Urban 48,332 90 % $1,368 (829–2,071) $2,264 (1,796–2,986) $1,154 (717–1,732)
Rural 5,311 10 % $1,224 (672–1,790) $2,040 (1,603–2,708) $1,134 (613–1,686)
Census Tract Median Income Quartiles
1st (<=$36,000) 13,336 25 % $1,216 (697–1,818) $2,045 (1,622–2,652) $1,106 (637–1,674)
2nd ($36,001–$47,500) 13,345 25 % $1,287 (781–1,985) $2,216 (1,751–2,942) $1,123 (695–1,709)
3rd ($47,501–$64,700) 13,409 25 % $1,385 (852–2,094) $2,239 (1,790–2,958) $1,168 (742–1,748)
4th (> = $64,701) 13,065 25 % $1,538 (959–2,287) $2,387 (1,882–3,159) $1,227 (778–1,812)
Comorbidities
0 33,742 63 % $1,390 (847–2,088) $2,256 (1,786–2,974) $1,160 (726–1,730)
1 12,889 24 % $1,324 (797–2,003) $2,240 (1,760–2,965) $1,157 (703–1,741)
2+ 7,022 13 % $1,227 (712–1,894) $2,231 (1,759–2,956) $1,099 (654–1,686)
Year of Diagnosis
2005 10,516 20 % $1,155 (648–1,765) $2092 (1,368–2,864) $1,070 (614–1,641)
2006 10,863 20 % $1,211 (706–1,871) $2134 (1,674–2,851) $1,074 (649–1,653)
2007 10,645 20 % $1,268 (766–1,949) $2131 (1,687–2,805) $1,073 (674–1,585)
2008 10,777 20 % $1,533 (966–2,188) $2285 (1,842–2,975) $1,252 (836–1,761)
2009 10,852 20 % $1,674 (1,065–2,368) $2389 (1,904–3,171) $1,316 (924–1,966)
aEnrollment based on age, fee-for-service, and equal parts A and B
bMissing (N): Race (30), Residential location (20), Median income (498)
cOther includes Hispanic, Asian, Native American and Other
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divided by receipt of biopsy or breast imaging and separ-
ately by receipt of MRI (Fig. 1). The median biopsy costs
were somewhat higher among the MRI group ($1,086 v.
$862; MRI vs. no MRI), but there were markedly lower
biopsy costs in the New Mexico and the Seattle SEER
registries for both diagnostic/preoperative groups (MRI
Table 2 Among the female SEER-Medicare breast cancer cohorta (2005–2009; N = 56,449), median and interquartile range (IQR) per
capita costs for women within the diagnostic/preoperative window (N = 53,653) by tumor characteristics, with and without breast
MRI
Total Median Costs MRI No MRI
(N = 53,653) (N = 10,776) (N = 42,877)
Characteristicsb of women N % Median IQR ($) Median IQR ($) Median IQR ($)
Total 53,653 100 % $1,353 (818–2,042) $2,251 (1,783–2,971) $1,152 (708–1,727)
Stage
0 8,533 16 % $1,721 (1,232–2,368) $2,627 (2,090–3,228) $1,524 (1,160–2,085)
I 25,146 47 % $1,393 (878–2,080) $2,255 (1,799–2,985) $1,190 (781–1,751)
II 14,328 27 % $1,106 (627–1,838) $2,093 (1,662–2,776) $891 (547–1,442)
III 3,838 7 % $1,008 (535–1,76) $2,078 (1,631–2,775) $825 (452–1,345)
IV 503 1 % $927 (449–1,685) $2,023 (1,690–2,791) $738 (405–1,294)
Unknown 1,305 2 % $1,310 (815–1,938) $2,118 (1,620–2,743) $1,176 (741–1,712)
Histology (invasive)
Ductal 33,134 62 % $1,259 (751–1,953) $2,186 (1,742–2,892) $1,068 (664–1,641)
Lobular 5,005 9 % $1,359 (765–2,061) $2,155 (1,736–2,837) $1,025 (615–1,576)
Mixed 3,177 6 % $1,346 (795–2,094) $2,264 (1,774–2,968) $1,058 (656–1,580)
Other 3,804 7 % $1,232 (714–1,877) $2,178 (1,623–2,927) $1,078 (648–1,674)
Grade
High 12,125 24 % $1,392 (877–2,083) $2,284 (1,811–3,050) $1,191 (772–1,754)
Intermediate 22,522 45 % $1,351 (822–2,054) $2,238 (1,776–2,944) $1,129 (708–1,715)
Low 15,133 30 % $1,289 (726–1,969) $2,212 (1,747–2,899) $1,100 (636–1,676)
Nodal Status
Positive 11,009 25 % $1,119 (623–1,851) $2,113 (1,652–2,842) $890 (534–1,439)
Negative 32,952 75 % $1,379 (847–2,074) $2,242 (1,788–2,951) $1,158 (739–1,734)
ER Status
Positive 40,999 84 % $1,367 (827–2,061) $2,249 (1,787–2,971) $1,152 (716–1,732)
Negative 7,978 16 % $1,263 (728–1,960) $2,231 (1,747–2,935) $634 (634–1,633)
Size
<1 cm 12,455 25 % $1,569 (1,090–2,253) $2,451 (1,967–3,184) $1,369 (987–1,936)
1 to <2 cm 19,135 39 % $1,348 (824–2,031) $2,187 (1,745–2,925) $1,127 (723–1,716)
2 to <5 cm 15,281 31 % $1,098 (610–1,826) $2,097 (1,660–2,798) $891 (532–1,459)
5+ cm 2,620 5 % $1,057 (535–1,870) $2,133 (1,719–2,810) $840 (438–1,420)
Primary Treatment
Mastectomy 19,650 37 % $1,267 (696–1,955) $2,265 (1,746–3,028) $1,053 (602–1,686)
BCSc without Radiation 12,972 24 % $1,362 (838–2,035) $2,285 (1,782–2,955) $1,198 (744–1,744)
BCSc with Radiation 21,031 39 % $1,413 (909–2,126) $2,230 (1,801–2,925) $1,201 (602–1,762)
Number of days in Diagnostic/
preoperative Window
<= Median (25 days) 27,779 52 % $1,172 (685–1,768) $2,009 (1,626–2,543) $1,056 (633–1,588)
> Median (25 days) 25,874 48 % $1,593 (998–2,354) $2,392 (1,878–3,229) $1,272 (828–1,915)
aEnrollment based on age, fee-for-service, and equal parts A and B
bMissing (N): Grade (3,873), Nodal status (9,692), ER status (4,598), Size (4,162)
cBCS: Breast Conserving Surgery
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v. no MRI). Compared with other regions in the diag-
nostic/preoperative MRI group, the highest biopsy me-
dian costs were found in Atlanta and San Francisco. For
those without diagnostic/preoperative MRI, the highest
biopsy costs were found in Detroit and New Jersey.
The unadjusted and adjusted (patient and tumor char-
acteristics) PCCs were similar overall and among the
diagnostic/preoperative MRI groups (Table 3). The total
adjusted cost difference between the MRI groups was
$1,065. Partitioning total costs by imaging and biopsy
costs, we found the difference was mainly attributable to
costs of imaging ($928).
Of the 38 % women (N = 20,570) who had at least one
breast event (MRI, Mammogram, Ultrasound or Biopsy)
during the preoperative period, 72 % (14,834/20,570) of
the women had an imaging event and 58 % (11,947/
20,570) had a biopsy. Within the diagnostic/periopera-
tive window, we found that in the diagnostic period, the
cost difference between the MRI and no MRI groups
was $185 ($159 for imaging and $31 for biopsy); in the
preoperative period, the difference was $369 ($779 for
imaging and $15 for biopsy; Table 3).
Discussion
Our study is the first to report diagnostic/preoperative
costs for breast cancer in the Medicare population, and
to compare those costs between women with and with-
out diagnostic/preoperative MRI in their clinical workup.
We found that the total adjusted PCC for the diagnos-
tic/preoperative period were $1,541 and were nearly
double for women with diagnostic/preoperative MRI
($2,382) compared to without ($1,317).
Diagnostic/preoperative costs did not differ dramatic-
ally over the study period, but decreased with more co-
morbidities, higher stage, and larger tumors. Geographic
variation in costs was greatest for biopsies, regardless of
receipt of diagnostic/preoperative MRI, and was very
low for imaging without diagnostic/preoperative MRI.
Overall, we found that diagnostic/preoperative MRI was
associated with higher PCCs by an estimated $1,065
after adjusting for patient and tumor characteristics.
However, the difference in imaging costs ($928) between
those with and without diagnostic/preoperative MRI was
considerably higher than the difference in biopsy costs
($138). Cost differences between the MRI v. no MRI
Fig. 1 Diagnostic/preoperative imaging and biopsy costs, with and without MRI, among female Medicare beneficiaries with breast cancer in SEER
registries (2005-2009)
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groups were more notable in the preoperative period
compared to the diagnostic period, which seems largely
attributable to the cost of MRI itself. The national pay-
ment amount for a bilateral MRI found in the physician
fee schedule (ref: http://www.cms.gov/apps/physician-
fee-schedule/search/) ranged from $994 to $905 in the
years 2007 to 2009; hence the imaging costs difference
of $928 found across the years in this study appears to
be due to the cost of an MRI.
Biopsy cost differences were minimal in both the diag-
nostic and preoperative periods. Thus, use of MRI in
diagnostic and preoperative workup for breast cancer
does not appear to lead to excess costs beyond the cost
of the MRI exam. These differences between the diag-
nostic/preoperative MRI groups as well as the cost
trends observed in the geographic, patient and tumor
characteristics provide an economic perspective of the
costs attributed to diagnostic/preoperative workup.
Our study is difficult to compare to prior literature,
given the lack of cost estimates for breast imaging and
biopsies in prior studies. However, estimating diagnos-
tic/preoperative costs in breast cancer overall, and in
relation to use of diagnostic/preoperative MRI is import-
ant for several reasons as cost measures: 1) provide crit-
ical inputs for comparative effectiveness research to
guide clinical decision making; 2) facilitate consumer-
centered public cost reporting; and 3) inform decisions
about costs once a breast cancer diagnosis occurs which
may influence women’s choices of initial treatment [3].
This study fills an important gap in our current under-
standing of the cost implications of diagnostic/preopera-
tive breast MRI. That is, while not conclusive, most
studies to date have not reported improved outcomes
from diagnostic/preoperative breast MRI, particularly for
reoperation and recurrence [5, 27–29]. Without clinical
benefit, the increased costs associated with diagnostic/
preoperative MRI might be interpreted as harmful to
women and health care systems. The results presented
here provide cost estimates, which can be combined
with measures needed to model harms from women’s
perspectives and which will be evaluated in relation to
any benefits, in comparative effectiveness models.
Public reporting of costs is an important component of
women’s ability to be knowledgeable about the likely cost
of breast cancer care and to make informed choices. The
Agency for Healthcare Research and Quality (AHRQ) re-
ported a general lack of consumer-centered cost reporting,
which is a necessary component for women to choose
high-value health care (when linked to quality) [14]. As
Keselman et al. note, patients need data to inform their
decisions to be effective health care consumers [30].
Relatedly, even though diagnostic/preoperative care is
only a portion of the costs of cancer care [2, 31, 32],
concern over costs once a diagnosis occurs may influ-
ence women’s choices of initial treatment [3]. Qualitative
evidence has revealed financial concerns and monetary
stress for women newly diagnosed with breast cancer
[3], which suggests that cost may play a role in plan-
ning initial treatment and breast cancer management.
Although this cross-sectional study was large,
population-based, and used publicly available data, sev-
eral limitations should be noted. First, we did not ac-
count for type of biopsy, such as core versus excisional,
which is likely to be associated with variation in cost.
Separate studies are currently underway to fully
characterize detailed aspects of diagnostic/preoperative
biopsy use in women with and without diagnostic/pre-
operative MRI. Furthermore, because claims data may
be inexact with respect to date of service and date
of claim, we performed a sensitivity analysis of our
Tables 3 Total crude (N = 53,653) and adjusted breast cancer per capita costs, with and without breast MRI and stratified by the
diagnostic and preoperative periods, among SEER-Medicare females (2005–2009)
Total Costs MRI No MRI MRI vs. No MRI
Na Nb PCCc Adjusted PCCb,c PCCc Adjusted PCCb,c PCCc Adjusted PCCb,c Differenced
Total 53,653 43,414 $1,560 $1,541 $2,524 $2,382 $1,318 $1,317 $1,065
Imaging costs 53,653 43,414 $455 $467 $1,227 $1,200 $261 $272 $928
Biopsy costs 53,653 43,414 $1,105 $1,074 $1,297 $1,183 $1,057 $1,045 $138
Diagnostic period 53,653 43,414 $1,127 $1,107 $1,313 $1,253 $1,080 $1,069 $185
I maging costs 52,487 42,491 $288 $293 $442 $418 $250 $259 $159
Biopsy costs 53,653 43,414 $845 $821 $884 $845 $835 $814 $31
Preoperative period 20,570 16,775 $1,131 $1,127 $1,356 $1,316 $932 $947 $369
Imaging costs 14,834 12,358 $627 $508 $912 $907 $127 $128 $779
Biopsy costs 11,947 9,504 $1,169 $1,165 $1,282 $1,173 $1,122 $1,158 $15
aUnadjusted N
bModel Ns after excluding patients with missing patient or tumor characteristics
cPCC: Per Capita Costs
dDifference between the MRI groups from the adjusted models
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definition of diagnostic/preoperative window to deter-
mine whether biopsies performed to establish the diag-
nosis may be classified as diagnostic/preoperative. Our
analyses were robust to the assessment of the ‘start’ of
the diagnostic/preoperative window based on the puta-
tive diagnostic biopsy. Also, as in all Medicare claims-
based studies, the potential for unmeasured confound-
ing exists, and our findings are only generalizable to the
Medicare population. Patterns of use and costs may be
different for women younger than the >65 yrs. old in-
cluded in this study. Another limitation of this claims-
based analysis is the lack of information on women’s
preferences and clinical decision making related to
breast cancer care. Finally, although not a limitation, we
do note that our cost measure approach (per capita
based on amount paid) is one of several methods to
evaluate cost. Another common approach is to use a
standardized national estimate for each type of service
and apply those costs to the services identified in claims.
The per capita amounts paid costs measures used in this
study are likely to be more useful at the individual
woman level for informing clinical decisions. The stan-
dardized national estimate approach may be better used
if one seeks to compare health care systems, do small
area analysis, or inform the societal perspective. Both of
these two methods are acceptable, but are different
“lenses” through which to interpret costs.
Conclusion
Since we found differences in total costs between the
MRI groups, the results suggest the excess costs associ-
ated with diagnostic/preoperative MRI could be factored
into women’s decisions as a potential harm (with the
marginal increase estimated at about $1,065). These esti-
mates may prove useful for those engaged in compara-
tive effectiveness studies of breast cancer diagnosis and
for women and their healthcare providers as they con-
sider alternative care pathways.
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